Takeda Pharmaceutical Co Ltd TAK-279 on Phase 2b Psoriasis Investor Call Transcript
Yes. Thank you very much, Chris, and welcome, everybody. Thank you for joining us at such an odd hour, Saturday night for those here in the U.S. and Sunday morning in Japan. And thank you for taking
(technical difficulty)
Yes. Can you hear me now, Chris? Terrific. I was just highlighting that we are coming off of an incredibly successful 2022 for Takeda R&D with really terrific momentum. I just wanted to share a few of the highlights.
Our dengue vaccine, QDENGA, was approved in Europe and in a number of endemic countries. And we had our filing at the FDA accepted. We had 3 Phase III study readouts that came out quite successfully: TAK-755 in TTP; ENTYVIO for graft versus host disease, where we just presented data at ECCO, very well-received; and the compound, the VEGF receptor inhibitor, that we just acquired ex-China rights from HUTCHMED, fruquintinib, which is approaching filing in the U.S. very shortly.
And then our mid- to late-stage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
